Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Brain Injuries, Craniocerebral Trauma, Trauma, Nervous System, Traumatic Brain Injury
Interventions: IV Propranolol and Per Tube Clonidine, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 16 Years to 64 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Plantar Fasciitis
Interventions: Intense Therapeutic Ultrasound Treatment - ITU; Device
Lead sponsor: Guided Therapy Systems; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Office Hysteroscopy and Endometrial Biopsy
Interventions: Misoprostol 50 mcg pesssary, Placebos; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 70 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: PTSD, Alcohol Use Disorder
Interventions: Pregabalin plus BBCET, Placebo plus BBCET; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Subjects
Interventions: 0.5 mg/kg Lpathomab, 1.0 mg/kg Lpathomab, 3.0 mg/kg Lpathomab, 10 mg/kg Lpathomab, 20 mg/kg Lpathomab, Saline solution for intravenous infusion; Biological · Other
Lead sponsor: Lpath, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Autism, Autism Spectrum Disorders
Interventions: Divalproex Sodium, Placebo Comparator; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 3 Years to 10 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Peripheral Vascular Diseases, Arterial Occlusive Diseases, Ischemia, Graft Occlusion, Vascular, Hyperplasia
Interventions: CGT003 (E2F Duplex Decoy); Drug
Lead sponsor: Anesiva, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 116
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 27
States / cities: Tucson, Arizona • Riverside, California • San Diego, California + 24 more

Conditions: Prediabetes
Interventions: Cocoa, Placebo; Other
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 40 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Healthy
Interventions: Lasmiditan, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 64 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: JNJ 28431754, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
Interventions: MCS110, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 7
States / cities: San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more

Conditions: Diabetes Mellitus, Type 1, Diabetes type1, Autoimmune Diabetes
Interventions: Bacillus Calmette-Guérin, Saline Injection; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Sleep Disorders, Circadian Rhythm
Interventions: Melatonin, Methylxanthine, Light Therapy; Drug · Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: Ibodutant 10 mg, Placebo; Drug
Lead sponsor: Menarini Group; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 65
States / cities: Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more

Conditions: Osteoarthritis
Interventions: Buprenorphine transdermal patch, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 44
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Cystic Fibrosis
Interventions: Losartan, placebo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 12 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Birmingham, Alabama • Miami, Florida • Kansas City, Kansas + 1 more

Conditions: Short Bowel Syndrome, Malabsorption, Malnutrition
Interventions: HPN Group Clinic Appointments using Mobile Devices (experimental), Mobile Device Access (placebo); Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 13 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Head and Neck Cancer
Interventions: fenretinide, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
Interventions: Tovinontrine (CRD-750), Placebo; Drug
Lead sponsor: Cardurion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 22
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 19 more

Conditions: Alcohol Use Disorder
Interventions: Arbaclofen Placarbil, Placebo; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Oakland Park, Florida

Conditions: Metastatic Pancreatic Cancer
Interventions: Anamorelin Hydrochloride, Placebo; Drug
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Hearing Loss, Noise-Induced
Interventions: Zonisamide 100Mg Cap, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acne Vulgaris
Interventions: CD5789 (trifarotene) 50μg/g cream, Placebo cream; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 9 Years and older
Enrollment: 1,208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 86
States / cities: Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 78 more

Search by objective public record fields.

DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury

Intense Therapeutic Ultrasound - Treatment for Chronic Plantar Fascia Musculoskeletal Pain Reduction

Misoprostol in Office Hysteroscopy and Endometrial Biopsy

Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD

A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers

A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG

Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures

Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection

Cocoa and Metabolic Health in Prediabetes

A Study of Lasmiditan in Healthy Japanese and Caucasian Participants

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes

Effectiveness of Combining Light and Non-Light Treatments for Jet Lag and Sleep Disorders

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

Losartan and Inflammation in Cystic Fibrosis

Home Parenteral Nutrition (HPN) Families' Mobile Distance Connections to Care Research

Fenretinide in Treating Patients With Leukoplakia of the Mouth

Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)

A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder

Anamorelin Study for Advanced Pancreatic Cancer

Noise-Induced Hearing Loss-Acute Exposure Treatment

Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris